Radiolabeled antibodies for therapy of infectious diseases

Ekaterina Dadachova, Arturo Casadevall

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Novel approaches to the treatment of infectious diseases are urgently needed. This need has resulted in renewing the interest in antibodies for therapy of infectious diseases. Radioimmunotherapy (RIT) is a cancer treatment modality that utilizes radiolabeled monoclonal antibodies. During the last decade we have translated RIT into the field of experimental fungal, bacterial, and HIV infections. In addition, successful proof of principle experiments with radiolabeled pan-antibodies that bind to antigens shared by major pathogenic fungi have been performed in vitro. The armamentarium of pan-antibodies would result in reducing our dependence on microorganism-specific antibodies and thus would speed up the development of RIT for infections. We believe that the time is ripe for deploying RIT in the clinic to combat infectious diseases.

Original languageEnglish (US)
Article numberAID-0023-2014
JournalMicrobiology spectrum
Volume2
Issue number6
DOIs
StatePublished - 2014

Fingerprint

Radioimmunotherapy
infectious disease
antibody
Communicable Diseases
Antibodies
Mycoses
Therapeutics
Bacterial Infections
HIV Infections
human immunodeficiency virus
antigen
Fungi
Monoclonal Antibodies
cancer
Antigens
microorganism
therapy
fungus
Infection
Neoplasms

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Microbiology (medical)
  • Ecology
  • Cell Biology
  • Genetics
  • Physiology

Cite this

Radiolabeled antibodies for therapy of infectious diseases. / Dadachova, Ekaterina; Casadevall, Arturo.

In: Microbiology spectrum, Vol. 2, No. 6, AID-0023-2014, 2014.

Research output: Contribution to journalArticle

Dadachova, Ekaterina ; Casadevall, Arturo. / Radiolabeled antibodies for therapy of infectious diseases. In: Microbiology spectrum. 2014 ; Vol. 2, No. 6.
@article{f70fa091a9774793b10fac3659c7a9d2,
title = "Radiolabeled antibodies for therapy of infectious diseases",
abstract = "Novel approaches to the treatment of infectious diseases are urgently needed. This need has resulted in renewing the interest in antibodies for therapy of infectious diseases. Radioimmunotherapy (RIT) is a cancer treatment modality that utilizes radiolabeled monoclonal antibodies. During the last decade we have translated RIT into the field of experimental fungal, bacterial, and HIV infections. In addition, successful proof of principle experiments with radiolabeled pan-antibodies that bind to antigens shared by major pathogenic fungi have been performed in vitro. The armamentarium of pan-antibodies would result in reducing our dependence on microorganism-specific antibodies and thus would speed up the development of RIT for infections. We believe that the time is ripe for deploying RIT in the clinic to combat infectious diseases.",
author = "Ekaterina Dadachova and Arturo Casadevall",
year = "2014",
doi = "10.1128/microbiolspec. AID-0023-2014",
language = "English (US)",
volume = "2",
journal = "Microbiology spectrum",
issn = "2165-0497",
publisher = "American Society for Microbiology",
number = "6",

}

TY - JOUR

T1 - Radiolabeled antibodies for therapy of infectious diseases

AU - Dadachova, Ekaterina

AU - Casadevall, Arturo

PY - 2014

Y1 - 2014

N2 - Novel approaches to the treatment of infectious diseases are urgently needed. This need has resulted in renewing the interest in antibodies for therapy of infectious diseases. Radioimmunotherapy (RIT) is a cancer treatment modality that utilizes radiolabeled monoclonal antibodies. During the last decade we have translated RIT into the field of experimental fungal, bacterial, and HIV infections. In addition, successful proof of principle experiments with radiolabeled pan-antibodies that bind to antigens shared by major pathogenic fungi have been performed in vitro. The armamentarium of pan-antibodies would result in reducing our dependence on microorganism-specific antibodies and thus would speed up the development of RIT for infections. We believe that the time is ripe for deploying RIT in the clinic to combat infectious diseases.

AB - Novel approaches to the treatment of infectious diseases are urgently needed. This need has resulted in renewing the interest in antibodies for therapy of infectious diseases. Radioimmunotherapy (RIT) is a cancer treatment modality that utilizes radiolabeled monoclonal antibodies. During the last decade we have translated RIT into the field of experimental fungal, bacterial, and HIV infections. In addition, successful proof of principle experiments with radiolabeled pan-antibodies that bind to antigens shared by major pathogenic fungi have been performed in vitro. The armamentarium of pan-antibodies would result in reducing our dependence on microorganism-specific antibodies and thus would speed up the development of RIT for infections. We believe that the time is ripe for deploying RIT in the clinic to combat infectious diseases.

UR - http://www.scopus.com/inward/record.url?scp=84957428369&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957428369&partnerID=8YFLogxK

U2 - 10.1128/microbiolspec. AID-0023-2014

DO - 10.1128/microbiolspec. AID-0023-2014

M3 - Article

AN - SCOPUS:84957428369

VL - 2

JO - Microbiology spectrum

JF - Microbiology spectrum

SN - 2165-0497

IS - 6

M1 - AID-0023-2014

ER -